Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
OABI 
OmniAb Inc. (OABI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: OABI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.86
1 Year Target Price $7.86
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -42.36% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 236.09M USD | Price to earnings Ratio - | 1Y Target Price 7.86 |
Price to earnings Ratio - | 1Y Target Price 7.86 | ||
Volume (30-day avg) 8 | Beta 0.94 | 52 Weeks Range 1.22 - 4.87 | Updated Date 08/29/2025 |
52 Weeks Range 1.22 - 4.87 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.13 | Actual -0.15 |
Profitability
Profit Margin -275.83% | Operating Margin (TTM) -416.19% |
Management Effectiveness
Return on Assets (TTM) -13.7% | Return on Equity (TTM) -22.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 216254856 | Price to Sales(TTM) 10.25 |
Enterprise Value 216254856 | Price to Sales(TTM) 10.25 | ||
Enterprise Value to Revenue 9.39 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 143955008 | Shares Floating 84854080 |
Shares Outstanding 143955008 | Shares Floating 84854080 | ||
Percent Insiders 11.84 | Percent Institutions 58.7 |
Upturn AI SWOT
OmniAb Inc.
Company Overview
History and Background
OmniAb, Inc. (fka Ligand Sciences) spun out of Ligand in 2022. It focuses on developing next-generation antibody therapeutics using its transgenic animal platforms.
Core Business Areas
- Antibody Discovery Platforms: OmniAb offers diverse transgenic animal platforms (OmniRat, OmniMouse, OmniFlic, OmniChicken) for antibody discovery. These platforms are licensed to pharmaceutical and biotechnology companies.
- Partnerships and Collaborations: OmniAb generates revenue through licensing agreements, milestone payments, and royalties from partnered programs.
Leadership and Structure
The CEO is Matt Foehr. The company operates with a structured management team overseeing research, development, and commercialization activities.
Top Products and Market Share
Key Offerings
- OmniRat: OmniRat is a rat-based platform that generates fully human antibodies. It is one of the flagship products of OmniAb. Data on market share is not available but it competes with other antibody discovery platforms like Harbour BioMed's H2L2 platform, Abcellera's AI powered drug discovery platform and distributed to companies with antibody discovery capabilities
- OmniMouse: OmniMouse is a mouse-based platform for generating human antibodies. Market share data is unavailable. It competes with similar technologies from companies like Regeneron(VELOCIMMUNEu00ae).
- OmniFlic: OmniFlic platform which enables discovery of bispecific antibodies. Market share data is unavailable, but competition includes other antibody engineering technologies.
- OmniChicken: OmniChicken generates diverse human antibodies from chicken. Competes with other transgenic animal platforms, and its market share is not publicly available.
Market Dynamics
Industry Overview
The antibody therapeutics market is experiencing strong growth due to the increasing prevalence of chronic diseases and advancements in antibody engineering technologies.
Positioning
OmniAb is positioned as a provider of advanced antibody discovery platforms, competing with other technology providers and internal R&D efforts of pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for antibody discovery platforms is estimated to be in the billions of dollars annually. OmniAb aims to capture a significant portion of this market through licensing and collaboration agreements.
Upturn SWOT Analysis
Strengths
- Proven antibody discovery platforms
- Diverse transgenic animal models
- Strong partnerships with pharmaceutical companies
- Potential for royalty revenue from partnered programs
Weaknesses
- Reliance on partners for clinical development and commercialization
- Limited control over the success of partnered programs
- Competition from other antibody discovery technologies
- Relatively small size and market capitalization
Opportunities
- Expanding partnerships with biotechnology and pharmaceutical companies
- Developing new antibody discovery platforms and technologies
- Targeting emerging therapeutic areas
- Acquiring complementary technologies or businesses
Threats
- Failure of partnered programs in clinical trials
- Competition from established antibody discovery companies
- Technological advancements that render existing platforms obsolete
- Economic downturn affecting pharmaceutical R&D spending
Competitors and Market Share
Key Competitors
- AbCellera (ABCL)
- Ligand Pharmaceuticals (LGND)
- Regeneron (REGN)
Competitive Landscape
OmniAb competes on the capabilities of its technology platforms. Success hinges on effective technology transfer and partner outcomes. Due to no publicly accessible detailed market share, the values of all market shares are assumed at 0.0.
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by partnerships and technology adoption; historical data is limited due to its recent spin-off.
Future Projections: Future growth relies on pipeline progression and successful partnerships; analyst projections should be consulted.
Recent Initiatives: Focus on expanding partnerships and developing new antibody discovery platforms.
Summary
OmniAb Inc., recently spun out, offers innovative antibody discovery platforms and its strength lies in its partnerships. It depends on its partner companies to successfully develop the technology into marketed drugs and should focus on expanding its collaboration agreements to ensure long-term revenue. The competition in the antibody discovery market is intense, so OmniAb needs to continually innovate its technologies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- OmniAb Inc. SEC filings
- Company website
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on available public information and represents an AI-based opinion. Investment decisions should be based on thorough research and consultation with a financial advisor. Market share data is often proprietary and estimations were used where direct figures were unavailable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 2022-11-02 | President, CEO & Director Mr. Matthew W. Foehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 114 | Website https://www.omniab.com |
Full time employees 114 | Website https://www.omniab.com | ||
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.